Loading...
XTAI
1737
Market cap198mUSD
Jul 09, Last price  
31.90TWD
1D
-0.16%
1Q
-0.31%
Jan 2017
8.87%
IPO
16.13%
Name

Taiyen Biotech Co Ltd

Chart & Performance

D1W1MN
XTAI:1737 chart
P/E
15.96
P/S
1.93
EPS
2.00
Div Yield, %
4.08%
Shrs. gr., 5y
-0.37%
Rev. gr., 5y
1.11%
Revenues
3.31b
+2.15%
1,980,143,0002,152,877,0002,298,251,0002,296,293,0002,408,819,0002,597,177,0002,761,204,0002,755,185,0002,757,075,0003,001,462,0002,906,615,0003,130,347,0004,095,651,0003,613,607,0003,408,811,0003,238,152,0003,307,660,000
Net income
400m
+7.63%
209,768,000181,410,000194,067,00078,105,000125,954,000214,469,000268,930,000351,967,000353,694,000452,741,000345,503,000365,085,000393,227,000426,704,000300,386,000371,524,000399,867,000
CFO
474m
-28.23%
358,023,000300,887,000246,089,000154,460,000203,212,000371,061,000383,926,000568,064,000607,866,000449,834,000330,807,000339,356,000600,076,000580,689,000454,539,000660,116,000473,766,000
Dividend
Aug 20, 20251.3 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1952 and headquartered in Tainan, Taiwan, Taiyen Biotech Co., Ltd. is a multifaceted enterprise engaged in the global production and distribution of salt-based goods. The company offers a wide-ranging portfolio that includes various salt and seawater-derived chemical products, alongside an array of personal care items such as bath salts, specialty soaps, and shampoos. Beyond hygiene products, their offerings extend to beverages, drinking water, and oral and optical care solutions like toothpaste, mouthwash, and contact lens maintenance fluids. Taiyen also provides specialized salts for cleaning produce, as well as food items and additives. Furthermore, the company manufactures pharmaceutical products, encompassing both cosmetic formulations and environmental health medications. Its operations also include the import and export of general consumer goods and beauty products, complemented by expert consulting services in industrial salt technology, covering supply, implementation, and management.
IPO date
Nov 18, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT